OBR Daily Commentary

forumImage

Roche’s Tecentriq Approved By European Commission As A First-line Monotherapy Treatment For People With A Type Of Metastatic Non-small Cell Lung Cancer

(Roche) May 5, 2021 - Roche today announced that the European Commission has approved Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression*, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. “We are delighted to bring Tecentriq to people in the EU with this specific type of lung cancer,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Tecentriq monotherapy has been shown to improve overall survival in people with high PD-L1 expression, when compared to chemotherapy, and therefore represents a new treatment option for people living with this difficult-to-treat disease.”

H. Jack West, MD (Posted: May 05, 2021)

quotesA fine alternative to pembrolizumab, which is the current standard of care in this setting after establishing a clear and sustained survival benefit over chemotherapy in the KEYNOTE-024 trial, but a lateral move that offers no incremental benefit over what we already have with pembrolizumab in this setting.quotes

Read Article arrow
Add Comment 1 Comment
forumImage

A Crisis of Undiagnosed Cancers is Emerging in the Pandemic’s Second Year

(ProPublica) May 4, 2021 - A factory worker didn’t want to call in sick or catch COVID-19, so she tried to ignore the pain. Now she has stage 4 cancer. Teresa Ruvalcaba lay on a bed in the emergency room of Chicago’s Mount Sinai Hospital, her right breast swollen to nearly twice the size of her left, the skin so thick and dimpled that the doctor examining her would note that it resembled an orange peel.

Ted Okon (Posted: May 04, 2021)

quotesThe world virtually stopped for COVID-19, but cancer did not. Now we are seeing the tragic impact of undiagnosed cancers due to a variety of reasons associated with the virus. COA is launching a major PSA Campaign — Time to Screen — with a celebrity spokesperson to make sure people get screened. In collaboration with CancerCare, we will not only motivate people to get screened but also help them find out where to get screened. This story in OBR is just one patient story. Unfortunately, there are a lot more stories unfolding everyday where patents are presenting with more advanced cancers. This is truly a human tragedy!quotes

Read Article arrow
Add Comment 1 Comment
forumImage

Takeda Closes in on Potential Approval for NSCLC Drug, Mobocertinib

(BioSpace) Apr 28, 2021 - Takeda’s non-small cell lung cancer (NSCLC) treatment Mobocertinib (TAK-788) is leading closer to regulatory approval after the U.S. Food and Drug Administration granted priority review to the New Drug Application. The FDA assigned a Prescription Drug User Fee Act (PDUFA) action date for Oct. 26.

H. Jack West, MD (Posted: May 01, 2021)

quotesMobocertinib doesn't offer activity at a level of osimertinib for EGFR mutated NSCLC or alectinib for ALK-positive NSCLC, and it presents some challenges in terms of tolerability, but it fulfills a real unmet need for this patient population. I know I and my patients with advanced NSCLC harboring an EGFR exon 20 insertion mutation would welcome having it approved and commercially available.quotes

Read Article arrow
Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Associate Clinical Professor, Medical Oncology Executi...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics Professo...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Steven Spielberg Family Chair in Hematology Oncology P...

member photo
Stephen M. Schleicher, M.D., MBA

Community Oncology, Medical Oncologist, OneOncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...